COPCOV: Chloroquine/Hydroxychloroquine prevention of COVID-19 in the healthcare setting

  • Funded by Bill & Melinda Gates Foundation, COVID-19 Therapeutics Accelerator Wellcome Trust
  • Total publications:12 publications

Grant number: 221307/Z/20/Z

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Bill & Melinda Gates Foundation, COVID-19 Therapeutics Accelerator Wellcome Trust
  • Principle Investigator

  • Research Location

    Thailand, South-East Asia
  • Lead Research Institution

    Mahidol Oxford Tropical Medicine Research Unit
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment


  • Age Group

    Adults (18 and older)

  • Vulnerable Population


  • Occupations of Interest

    Health PersonnelHospital personnel


There is no proven treatment, chemoprophylaxis or vaccine for COVID-19. This is the most serious pandemic emergency for 100 years. Healthcare workers are being affected disproportionately in the continuing epidemic threatening an imminent breakdown of health services. Chloroquine and hydroxychloroquine are safe and well-tolerated medications which can be taken for years without adverse effects.Both have significant antiviral activity against SARS-CoV-2 and there is emerging evidence from China and Europe of efficacy in treatment. Unfortunately there is also premature recommendation from countries such as India which now recommends low dose hydroxychloroquine for prophylaxis in health care workers. We propose conducting a multi-centre, multi-country randomised, double blind, placebo controlled assessment of the prophylactic efficacy of chloroquine (Asia) or hydroxychloroquine (Europe) in preventing COVID-19 illness in at-risk healthcare workers and other frontline staff. At least 40,000 participants in Asia and Europe will be randomised 1:1 to receive chloroquine or hydroxychloroquine or a matched film coated placebo as daily prophylaxis for three months. The study's objectives are the prevention of symptomatic coronavirus disease (COVID-19) and the attenuation of the clinical severity.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Diversity of Human Enterovirus Co-Circulations in Five Kindergartens in Bangkok between July 2019 and January 2020.

The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions.

WHO COVID-19 therapeutic guidelines - Authors' reply.

Does hydroxychloroquine still have any role in the COVID-19 pandemic?

No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency.

Guidelines should not pool evidence from uncomplicated and severe COVID-19.

COVID-19 chemoprevention.

Solutions to COVID-19 data sharing.

COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.